Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Tuberculosis (TB) is the leading cause of death from a single infectious agent, requiring at
least 6 months of multidrug treatment to achieve cure. However, the lack of reliable data on …

Background Approximately 5% of patients with drug-susceptible tuberculosis have a relapse
after 6 months of first-line therapy, as do approximately 20% of patients after 4 months of …

Rationale: Acquired resistance is an important driver of multidrug-resistant tuberculosis (TB),
even with good treatment adherence. However, exactly what initiates the resistance and …

Background High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM).
Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human …

Tuberculosis (TB) elimination requires innovative approaches. The new Global Tuberculosis
Network (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in …

Rationale: We examined whether increased rifampin doses could shorten standard therapy
for tuberculosis without increased toxicity. Objectives: To assess the differences across three …

The introduction of rifampicin (rifampin) into tuberculosis (TB) treatment five decades ago
was critical for shortening the treatment duration for patients with pulmonary TB to 6 months …

Background Levofloxacin is used for the treatment of multidrug-resistant tuberculosis;
however the optimal dose is unknown. Methods We used the hollow fiber system model of …

Although tuberculosis (TB) is a curable disease, it remains the foremost cause of death from
a single pathogen. Globally, approximately 1.6 million people died of TB in 2017. Many …